Synapsoft logo
AI Insights from Disclosures
Searching...
Hugel, Inc. 145020
Searching...

Company Summary

Quarterly Performance Revenue Operating Margin

Market Sentiment

※ Click the graph to view AI analysis information for that month.
Revenue
Consolidated
Separate
Operating Income
Consolidated
Separate
Net Income
Consolidated
Separate

Financials

Excel

No financial data is available for this period.
~
Quarterly
Annual
No data is available for this period.

*Values beyond the fourth decimal place of the unit are displayed as '0/-0'

Financial Indicator Forecast

※ These forecasts are simple AI estimates based on historical data and may differ from actual results.

Company Overview

as of June 2026
Hugel, Inc. researches, develops, and manufactures biopharmaceuticals utilizing botulinum toxin type A, based on the microorganism Clostridium botulinum. On January 31, 2018, the company absorbed and merged its wholly owned sales subsidiary, Hugel Pharma Co., Ltd., and as of the reporting date operates the sale of biopharmaceuticals such as Botulax (botulinum toxin) and The Chaeum (HA filler) through its internal Sales and Marketing Division.
Representative Director Doohyun Chang
Founded November 22, 2001
Corporation Type KOSDAQ
Industry Classification Manufacture of medicinal chemicals
Corporate number 11011-2380890
Business number 211-87-04515
Phone Number 02-6966-1600
Fax Number 02-6966-1691
Website www.hugel.co.kr
Company Address 23 Geodudanji 1-gil, Dongnae-myeon, Chuncheon-si, Gangwon-do
Products & Services

Financial Health

Executives

Employees

Shareholders

Industry revenue

Disclosures

Comments

0 / 255

AI Assistant